Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.70 USD
Change Today -0.69 / -15.72%
Volume 3.3M
CYTR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$4.32
Previous Close
$4.39
Day High
$4.33
Day Low
$3.68
52 Week High
06/13/14 - $5.46
52 Week Low
12/16/14 - $2.08
Market Cap
206.2M
Average Volume 10 Days
1.8M
EPS TTM
$-0.94
Shares Outstanding
55.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

26 Employees
Last Reported Date: 03/10/15
Founded in 1985

cytrx corp (CYTR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.3M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Drug Development
Total Annual Compensation: $650.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2014.

cytrx corp (CYTR) Key Developments

CytRx Corporation Announces Board Changes

CytRx Corporation announced that it has increased the number of directors of the company from five to six and appointed Eric J. Selter as a member of Board of Directors. The board also appointed Mr. Selter as the Chairman of the Audit Committee and as a member of the Compensation Committee of Board. Such positions include Chief Operating Officer since 2000, Senior Vice President since 2006, and Secretary from 2006 to 2011, then again from 2013 to present.

CytRx Corporation Reports Unaudited Financial Results for the First Quarter Ended March 31, 2015

CytRx Corporation reported unaudited financial results for the first quarter ended March 31, 2015. For the quarter, the company’s net loss was $17,524,550, or $0.31 per diluted share, compared with a net gain of $4,664,518, or $0.08 per diluted share, for the quarter ended March 31, 2014. Loss before other loss was $15,693,977 against $10,118,922 a year ago.

CytRx Corporation Reports Earnings Results for the Year Ended December 31, 2014

CytRx Corporation reported earnings results for the year ended December 31, 2014. For the year, the company reported licensing revenue of $100,000, compared to $300,000 for the year ended December 31, 2013. Loss before other income for the year ended December 31, 2014 was $49.60 million, compared to a loss before other income of $27.59 million for the year ended December 31, 2013. Interest income for the year ended December 31, 2014 was $305,331, compared to $137,676 for the year ended December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $3.70 USD -0.69

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,062.0x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,283.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.